Rangeley Capital, LLC
Q3 2025 13F-HR Holdings
Net value change ($000)
+31,761
(37.9%)
New positions
73
Sold out positions
22
Turnover %
50.3%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2025
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| YEXT | 4,643 | NEW |
| TACO | 3,297 | NEW |
| SATS | 1,756 | NEW |
| WOW | 1,648 | 50.8% |
| LQDA | 1,160 | NEW |
| ABUS | 1,141 | 42.7% |
| CCOI | 1,139 | NEW |
| PRTA | 1,128 | 26.0% |
| SEPN | 1,036 | 167.4% |
| CDZI | 1,034 | 73.8% |
Top Reduces (Value $000, Stocks/ETFs)
| Sage Therapeutics, Inc. | -6,658 | -100.0% |
| iTeos Therapeutics, Inc. | -3,012 | -100.0% |
| SKAA | -2,272 | -100.0% |
| Third Harmonic Bio, Inc. | -1,575 | -100.0% |
| WBA | -1,171 | -100.0% |
| SGRY | -1,009 | -27.3% |
| AMPY | -843 | -94.1% |
| Verve Therapeutics, Inc. | -696 | -100.0% |
| BPMC | -641 | -100.0% |
| Vigil Neuroscience, Inc. | -539 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
9,051
(7.8% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|